Juvista in the Non-surgical Improvement of Existing Scars

NCT00821457 | Withdrawn

• 1 other identifier: RN1001-0098
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Renovo, a Biopharmaceutical company involved in the development of drugs to improve the appearance of scars and enhance wound healing, are proposing to carry out research in improving the appearance of existing scars that are 2-6 months old using Juvista. Juvista has not previously been administered to pre-existing scars without surgical revision, but it is thought that some beneficial effects seen with Juvista in previous trials may also be seen when administered to existing scars whilst the scar is maturing. This proof of concept study will therefore investigate the effect of Juvista in Caucasian male and female patients when administered to scars that are between two and six months old. Scarring in the skin can vary hugely between individuals; therefore the most reliable way to assess the efficacy of an improvement of scar appearance is to use a model where each patient acts as their own control. A placebo will also be used for this trial as there are currently no approved pharmaceuticals for the improvement of scarring. A total of 20 patients will be allocated to one of two dosing groups. Patients who enter the study will have linear scars resulting from broken skin (e.g. trauma, surgery) between 7 and 20cm in length, as well as meeting other specific criteria. The scar to be treated will be divided into two equal segments. Each segment will receive an intradermal injection of Juvista or placebo on Day 0 and 24 hours later. The measure of change in scar appearance will be performed using colour analysis which will assess the change in colour between the Juvista treated segments versus the placebo treated segment of the scar, with reference to the surrounding skin within each patient.

Conditions

Scars

Keywords

existing scars the are two to six months old

Outcome Measures

Primary Outcomes (1)

• The primary efficacy variable is the change in scar appearance at 6 months post treatment, assessed by calculating the colour difference between the treated scar sections with reference to the surrounding skin.

  6 months post treatment

Secondary Outcomes (1)

• The secondary efficacy variable is the difference in scar appearance between active and placebo treated segments at 6 months post treatment as assessed using a global scar comparison scale

  6 months post treatment

Study Arms (2)

Group 1

ACTIVE COMPARATOR

250ng Juvista vs placebo

Drug: Juvista; Drug: Placebo

Group 2

ACTIVE COMPARATOR

500 ng Juvista vs placebo

Drug: Placebo; Drug: Juvista

Interventions

Juvista DRUG

250ng

Also known as: Avotermin, Recombinant Transforming Growth Factor Beta 3

Group 1

Placebo DRUG

Powder for solution for injection

Group 1; Group 2

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male and Female Caucasian patients aged 18-45 years who have provided written informed consent.
• A body mass index between 15 and 35 kg/m2 (calculated using Quetelet's index \[weight (kg)/height m2\]
• Patients with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol (see Section 6.4.2). All laboratory tests must be performed within 28 days of the first trial dose administration.
• Female patients of child bearing potential who are using a highly effective method(s) of contraception and agree to do so from at least the screening visit until one month after administration of the final study dose. For the purposes of the protocol, highly effective method(s) of contraception will be defined as consistently and correctly used implants, injectables, combined oral contraceptives, sexual abstinence or a vasectomised partner
• The scar to be treated is 2-6 months old at Day 0.
• The scar is linear.
• The scar to be treated is symmetrical in appearance around the mid-line.
• The scar to be treated is between 7cm and 20cm in length and a maximum of 1cm in width.
• The scar to be treated runs along a flat surface which is in the same focal plane and suitable for accurate medical photography.

You may not qualify if:

• Patients who on direct questioning and / or physical examination, have evidence of any past or present clinically significant medical condition that would impair wound healing including :
• Significant rheumatoid arthritis.
• Significant hepatic impairment (LFTs \>3 times upper limit of normal).
• Inadequately or uncontrolled congestive heart failure.
• Currently active malignancy or history of any malignancy in the 5 years prior to the screening visit.
• Immunosuppression or chemotherapy in the twelve months prior to the screening visit.
• A history of radiotherapy to the study scar area.
• Diabetes mellitus (unless controlled by diet and exercise alone).
• A bleeding disorder or current use of anti-thrombotic therapy (aspirin, ticlopidine and clopidogrel are permitted).
• Patients with a creatinine clearance (CLcr) of 80ml/min or less. Creatinine clearance will be determined from the serum creatinine level at pre-study screening using the following formula :
• o CLcr = (140-age (years)) x weight(kg)/ 72 x serum creatinine (mg/dL) { x 0.85 for females }
• Patients with a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
• Patients with a history of clinically relevant allergy, hypersensitivity, angioedema, or anaphylaxis.
• Patients with a progressive neurological condition including Parkinson's disease, Alzheimer's disease and uncontrolled epilepsy.
• Patients with a known history of chronic viral infection (Hepatitis, HIV) or ongoing active infection.

Sponsors & Collaborators

• Renovo: lead

Study Sites (1)

Renovo Clinical Trial Unit

Manchester, Greater Manchester, WA5 8GG, United Kingdom

Location

MeSH Terms

Conditions

Cicatrix

Interventions

TGFB3 protein, human

Condition Hierarchy (Ancestors)

Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• James Dr Bush, MBChB MRCS

  Renovo

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: January 12, 2009
• First Posted: January 13, 2009
• Study Start: January 1, 2009
• Primary Completion: March 1, 2010
• Study Completion: March 1, 2010
• Last Updated: March 9, 2010

Record last verified: 2010-03

Locations

GB (1)